| Original language | English |
|---|---|
| Pages (from-to) | 1425-1426 |
| Number of pages | 2 |
| Journal | JAMA Oncology |
| Volume | 4 |
| Issue number | 10 |
| DOIs |
|
| Publication status | Published - 1 Oct 2018 |
| Externally published | Yes |
Funding
Author Affiliations: Department of Medical Psychology, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands (Hillen, Smets, van Maarschalkerweerd); Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Woei-A-Jin); Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands (van Laarhoven, Sommeijer). Published Online: August 23, 2018. doi:10.1001/jamaoncol.2018.3495 Author Contributions: Dr Hillen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Hillen, Smets, van Laarhoven, Sommeijer. Acquisition, analysis, or interpretation of data: Hillen, Woei-A-Jin, van Maarschalkerweerd, van Laarhoven, Sommeijer. Drafting of the manuscript: Hillen, Sommeijer. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Hillen. Obtained funding: Hillen. Administrative, technical, or material support: Hillen, Sommeijer. Supervision: Woei-A-Jin, Smets, van Laarhoven. Coding data: van Maarschalkerweerd. Conflict of Interest Disclosures: Dr van Laarhoven reported serving in a consulting or advisory role for Eli Lilly and Company and Nordic Pharma and receiving research funding from Bayer, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly and Company, Nordic Pharma, Philips, and Hoffmann-La Roche. No other disclosures were reported. Funding/Support: Financial support for this study was provided by grant UVA 2014-6671 from the Dutch Cancer Society (KWF Kankerbestrijding) (Dr Hillen).